SPONSOR
Hoffmann-La Roche
Total Trials
12
Recruiting
12
Phases
Phase 1, Phase 4, Phase 1, Phase 2, Phase 3, Phase 2
Conditions studied: Multiple SclerosisMuscular Atrophy, SpinalBreast CancerMature B-Cell Non-Hodgkin LymphomaCarcinoma, Non-Small-Cell LungHealthy VolunteersModerately to Severely Active Crohns DiseaseRelapsing Multiple SclerosisMultiple MyelomaNon-Small Cell Lung Cancer
Hoffmann-La Roche is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including Multiple Sclerosis, Muscular Atrophy, Spinal, Breast Cancer, Mature B-Cell Non-Hodgkin Lymphoma.
The trial portfolio spans Phase 1, Phase 4, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hoffmann-La Roche
How many clinical trials has Hoffmann-La Roche sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by Hoffmann-La Roche, of which 12 are actively recruiting participants. These trials cover conditions including Multiple Sclerosis, Muscular Atrophy, Spinal, Breast Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hoffmann-La Roche research focus on?
Hoffmann-La Roche clinical trials span Multiple Sclerosis, Muscular Atrophy, Spinal, Breast Cancer, Mature B-Cell Non-Hodgkin Lymphoma, Carcinoma, Non-Small-Cell Lung, and additional conditions. The research pipeline includes Phase 1, Phase 4, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Hoffmann-La Roche clinical trial?
To participate in a Hoffmann-La Roche trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hoffmann-La Roche trials with current recruitment status updated daily.
Clinical Trials by Hoffmann-La Roche
NCT05704361 Phase 1
Recruiting
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Multiple Sclerosis
NCT05861999 Phase 4
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Muscular Atrophy, Spinal
NCT06274515 Phase 4
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
Breast Cancer
NCT05533775 Phase 1, Phase 2
Recruiting
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mature B-Cell Non-Hodgkin Lymphoma
NCT06862869
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Carcinoma, Non-Small-Cell Lung
NCT07271693 Phase 1
Recruiting
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants
Healthy Volunteers
NCT07298421 Phase 3
Recruiting
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
NCT07161258 Phase 2
Recruiting
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
NCT07405801 Phase 2
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Breast Cancer
NCT07555938 Phase 3
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Multiple Myeloma
NCT05789082 Phase 1, Phase 2
Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-Small Cell Lung Cancer
NCT05894239 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Metastatic Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology